pharma · Early Childhood Caries · Acute Myeloid Leukemia
University of Hong
The University of Hong Kong
University of Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Early Childhood Caries, Acute Myeloid Leukemia, Influenza Virus Infection, Smoking Cessation, Influenza. NovaPharma
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 42
- Drugs
- 71
- Patents
- 0
Brolucizumab
Approved · small molecule · Age-Related Macular Degeneration
Brolucizumab for Age-Related Macular Degeneration is a Approved program (small_molecule) at The University of Hong Kong with 1 ClinicalTrials.gov record(s).
Internal code Switch Study
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- The University of Hong Kong
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Age-Related Macular Degeneration
- Status
- completed
- Trials
- 1